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A bs tr ac t
Background
Glycoprotein IIb/IIIa inhibitors are indicated in patients with acute coronary syn-
dromes who are undergoing an invasive procedure. The optimal timing of the initia-
tion of such therapy is unknown.
Methods
We compared a strategy of early, routine administration of eptifibatide with delayed, 
provisional administration in 9492 patients who had acute coronary syndromes with-
out ST-segment elevation and who were assigned to an invasive strategy. Patients were 
randomly assigned to receive either early eptifibatide (two boluses, each containing 
180 μg per kilogram of body weight, administered 10 minutes apart, and a standard 
infusion ≥12 hours before angiography) or a matching placebo infusion with provi-
sional use of eptifibatide after angiography (delayed eptifibatide). The primary effi-
cacy end point was a composite of death, myocardial infarction, recurrent ischemia 
requiring urgent revascularization, or the occurrence of a thrombotic complication 
during percutaneous coronary intervention that required bolus therapy opposite to 
the initial study-group assignment (“thrombotic bailout”) at 96 hours. The key sec-
ondary end point was a composite of death or myocardial infarction within the first 
30 days. Key safety end points were bleeding and the need for transfusion within the 
first 120 hours after randomization.
Results
The primary end point occurred in 9.3% of patients in the early-eptifibatide group 
and in 10.0% in the delayed-eptifibatide group (odds ratio, 0.92; 95% confidence 
interval [CI], 0.80 to 1.06; P = 0.23). At 30 days, the rate of death or myocardial in-
farction was 11.2% in the early-eptifibatide group, as compared with 12.3% in the 
delayed-eptifibatide group (odds ratio, 0.89; 95% CI, 0.79 to 1.01; P = 0.08). Patients 
in the early-eptifibatide group had significantly higher rates of bleeding and red-cell 
transfusion. There was no significant difference between the two groups in rates of 
severe bleeding or nonhemorrhagic serious adverse events.
Conclusions
In patients who had acute coronary syndromes without ST-segment elevation, the 
use of eptifibatide 12 hours or more before angiography was not superior to the 
provisional use of eptifibatide after angiography. The early use of eptifibatide was 
associated with an increased risk of non–life-threatening bleeding and need for 
transfusion. (ClinicalTrials.gov number, NCT00089895.)
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The optimal timing for the initia-tion of treatment with glycoprotein IIb/IIIa inhibitors in patients who have acute coro-
nary syndromes without ST-segment elevation and 
are undergoing invasive procedures has not been 
determined. It is also not clear whether such treat-
ment should be administered routinely to all such 
patients before the procedure or whether such 
treatment should be provisional. The 2007 guide-
lines of the American College of Cardiology and 
the American Heart Association1 recommend that 
patients with high-risk features receive aspirin and 
either clopidogrel or a glycoprotein IIb/IIIa inhibi-
tor before angiography (i.e., early therapy) (class I 
recommendation). The European Society of Car-
diology favors early dual antiplatelet therapy with 
aspirin and clopidogrel (class I recommendation), 
with the addition of a glycoprotein IIb/IIIa in-
hibitor reserved for patients with an elevated tro-
ponin level, ST-segment depression, or diabetes 
(Class IIa recommendation).2 These differences 
reflect the undefined role of glycoprotein IIb/IIIa 
inhibitors in the treatment of patients with acute 
coronary syndromes, since most of the recommen-
dations were based on data from studies per-
formed before the introduction of intensive medi-
cal therapy, contemporary interventional devices, 
and higher-dose regimens of glycoprotein IIb/IIIa 
inhibitors.3,4
We conducted the Early Glycoprotein IIb/IIIa 
Inhibition in Non–ST-Segment Elevation Acute 
Coronary Syndrome (EARLY ACS) trial to test the 
hypothesis that a strategy of early, routine admin-
istration of the glycoprotein IIb/IIIa inhibitor ep-
tifibatide would be superior to delayed, provisional 
administration of the drug in reducing ischemic 
complications among high-risk patients.
Me thods
Study Design
Our trial was a collaboration involving the Virtual 
Coordinating Center for Global Collaborative Car-
diovascular Research (VIGOUR), the Thromboly-
sis in Myocardial Infarction (TIMI) Study Group, 
and a steering committee of investigators. An in-
dependent data and safety monitoring board re-
viewed the trial’s progress and adverse events. In-
vestigators at the Duke Clinical Research Institute 
(DCRI) coordinated the trial, collected and man-
aged the data, provided statistical support, and 
classified clinical events. Treatment codes were 
generated and held by a statistician at the DCRI 
who was aware of study-group assignments. The 
final trial database and treatment codes were trans-
ferred to one of the two initial sponsors, Schering-
Plough, at the end of the trial on December 17, 
2008. All analyses were performed by the DCRI 
with the use of the complete database. The aca-
demic authors on the executive committee (with 
input from the steering committee) prepared all 
drafts of the manuscript, decided to submit the 
article for publication, and assume responsibil-
ity for the accuracy and completeness of the re-
ported data.
The original protocol and amendments were 
approved by the ethics committee at each center. 
All patients provided written informed consent.
Study Population
We randomly assigned 9492 patients who had 
high-risk acute coronary syndromes without ST-
segment elevation and were assigned to an inva-
sive strategy to receive either early, routine ad-
ministration of eptifibatide or early placebo with 
delayed, provisional administration of eptifibatide 
after angiography but before the patient under-
went a percutaneous coronary intervention (PCI). 
Patients who were at least 18 years of age were 
eligible if they had cardiac ischemia at rest last-
ing for at least 10 minutes and occurring within 
24 hours before randomization and if they un-
derwent randomization within 8 hours after pre-
sentation, with a planned invasive strategy no 
sooner than the next calendar day after random-
ization. Patients were considered to have a high-
risk condition if they met two or more of the 
following criteria: ischemic changes on electro-
cardiography (ST-segment depression of 0.1 mV 
or more or transient [<30-minute] ST-segment el-
evation of 0.1 mV or more in two or more con-
tiguous leads), a level of troponin or creatine ki-
nase MB that was above the upper limit of the 
normal range, and an age of 60 years or more.
Key exclusion criteria were an increased risk 
of bleeding, an allergy to heparin or eptifibatide, 
pregnancy, renal dialysis within the previous 30 
days, the intention of the investigator to use a non-
heparin anticoagulant, recent use of a glycoprotein 
IIb/IIIa inhibitor, and any other condition that 
posed an increased risk.5
A protocol amendment on June 3, 2005, ex-
panded the randomization period to 12 hours after 
presentation, clarified the timing of angiography 
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(≥12 hours after randomization), and permitted 
the enrollment of patients who were designated 
as high risk and who were between the ages of 
50 and 59 years with elevated levels of troponin or 
creatine kinase MB if they had documented coro-
nary, cerebrovascular, or peripheral artery disease. 
On March 24, 2008, a protocol amendment re-
duced the sample size to 9500 patients.
Study Procedures
Eligible patients were randomly assigned in a 1:1 
ratio to receive either early, routine administration 
of eptifibatide or early administration of placebo 
with delayed, provisional administration of epti-
fibatide. Randomization was performed in blocks 
according to the study center and was stratified 
according to the intention of the investigator to ad-
minister early clopidogrel (i.e., at or before ran-
domization). Randomization was managed through 
an interactive voice-response system.
After randomization, patients received either 
early eptifibatide in two boluses, each containing 
180 μg per kilogram of body weight, or matching 
placebo boluses administered 10 minutes apart. 
A standard infusion of 2.0 μg of eptifibatide or 
matching placebo per kilogram per minute (or 
1.0 μg per kilogram per minute if the creatinine 
clearance was less than 50 ml per minute) was 
administered concurrently with the first bolus. In 
cases of bleeding, the Investigator could decrease 
the dose of the study-drug infusion by one third.
After coronary angiography but before PCI, in-
vestigators could request a PCI study-drug kit for 
patients who they deemed would benefit from ep-
tifibatide on the basis of the clinical evidence and 
angiographic findings. The first bolus of the PCI 
study-drug kit contained eptifibatide for patients 
who had previously received placebo and placebo 
for patients who had previously received eptifib-
atide. Concurrently, the blinded administration 
of the initial study drug (either eptifibatide or 
placebo) was stopped, and an open-label infusion 
of eptifibatide was begun and continued for 18 to 
24 hours after the PCI procedure.
If a provisional dose of a study drug was not 
administered before PCI, the initial infusion was 
continued without a change for 18 to 24 hours 
after PCI. During PCI, if a thrombotic complica-
tion occurred after the catheter guidewire crossed 
the lesion, investigators could request a kit that 
contained bolus therapy opposite to the initial 
study-group assignment (termed a bailout kit). The 
use of bailout kits for any one of seven predefined 
procedural complications5 was considered “throm-
botic bailout,” and such cases were reviewed by the 
clinical events committee.
For patients undergoing PCI, the duration of 
the infusion was 96 hours or less; longer infusions 
were permitted to ensure a minimum 18-hour in-
fusion after PCI. For patients undergoing coro-
nary-artery bypass grafting (CABG), the infusion 
continued until 2 hours before surgery (maximum 
infusion time, 120 hours). Patients who were not 
undergoing revascularization received an infusion 
for no more than 96 hours.
Concomitant Medications
Aspirin (at a dose of 162 to 325 mg orally or 150 
to 500 mg intravenously) was required on enroll-
ment, followed by at least 75 mg daily thereafter. 
Thienopyridine was substituted in patients who 
could not tolerate aspirin.
The protocol mandated the administration of 
either weight-based unfractionated heparin or 
enoxaparin adjusted for weight and creatinine 
clearance (with the possible substitution of dal-
teparin or nadroparin if enoxaparin was unavail-
able), according to the investigator’s choice. For 
patients undergoing PCI who received unfraction-
ated heparin, the target for the activated clotting 
time was 250 seconds; for patients receiving enox-
aparin, additional enoxaparin (0.3 mg per kilo-
gram) was administered intravenously if PCI 
was performed 8 to 12 hours after the last dose. 
Switching between unfractionated heparin and 
low-molecular-weight heparins was discouraged 
because of the potentially increased risk of bleed-
ing.6 The initial protocol amendment permitted 
the use of bivalirudin during PCI. The March 24, 
2008, amendment allowed the use of bivalirudin 
and fondaparinux as baseline antithrombotic 
therapy.
If early clopidogrel was used, the recommended 
loading dose was 300 mg. A 600-mg loading dose 
was permitted during PCI if no previous loading 
dose had been administered. The recommended 
maintenance dose of clopidogrel was 75 mg daily. 
Other medical therapies were administered ac-
cording to standard practice and guidelines.
Key End Points
The primary efficacy composite end point was 
death from any cause, myocardial infarction, re-
current ischemia requiring urgent revasculariza-
tion, or thrombotic bailout at 96 hours (for details, 
see Section 2 in the Supplementary Appendix, avail-
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able with the full text of this article at NEJM.
org).7 The key secondary efficacy end point was a 
composite of death from any cause or myocardial 
infarction within the first 30 days. Safety end points 
included rates of hemorrhage, transfusion, surgi-
cal reexploration, stroke, thrombocytopenia, and 
serious adverse events at 120 hours after random-
ization. Stroke and all efficacy components, ex-
cept death, were adjudicated by an independent 
clinical events committee whose members were 
unaware of study-group assignments. If classifi-
cation of TIMI bleeding could not be determined 
by a programmed algorithm, blinded adjudication 
was performed.
Statistical Analysis
Efficacy analyses were performed according to the 
intention-to-treat principle. In patients with mul-
tiple events, the earliest end point was counted. 
Event rates were compared with the use of the 
Cochran–Mantel–Haenszel test, with adjustment 
for intended early use of clopidogrel. Odds ratios 
with 95% confidence intervals were calculated. 
Prespecified subgroup analyses were performed 
on the basis of sex, geographic region, baseline 
troponin level, type of hospital (primary care or 
tertiary care), presence or absence of diabetes, age 
(<75 years or ≥75 years), the type of antithrombin 
that was used, TIMI risk score, and the time from 
presentation to randomization (≤4 hours or >4 
hours). Logistic-regression models tested for inter-
action with study-group assignments in selected 
subgroups. The Breslow–Day test was used to as-
sess for heterogeneity of the odds ratios within 
clopidogrel strata and subgroups.
Safety end points were summarized for the as-
treated population (with the exclusion of 77 pa-
tients who did not receive any study drug). Be-
tween-group comparisons were performed with 
the use of Pearson’s chi-square test to analyze the 
rate of stroke, and the Cochran–Mantel–Haenszel 
test with adjustment for intended early use of 
clopidogrel was used to analyze end points that 
involved bleeding.
The initial sample size (10,500 patients) pro-
vided a power of 85% to detect a 22.5% relative 
reduction in the rate of the primary efficacy end 
point in the early-eptifibatide group, as compared 
with the delayed-eptifibatide group, assuming a 
96-hour event rate of 5.8% in the latter group. This 
sample size preserved a power of 85% to detect 
a 15% reduction in the rate of death or myocar-
dial infarction at 30 days in the early-eptifibatide 
group. The executive committee regularly reviewed 
pooled event rates in a blinded fashion. Since the 
rate of the observed composite primary end point 
was nearly twice the initial projection (5.2%) after 
the enrollment of 6822 patients, the executive 
committee recommended a sample-size reduction 
to 9500 patients, which provided a power of 98% 
for the composite primary end point and 81% for 
the composite secondary end point.
One prespecified interim efficacy analysis was 
conducted after approximately 50% of the pa-
tients had been enrolled. O’Brien–Fleming stop-
ping boundaries were generated for between-group 
comparisons, with a one-sided nominal alpha level 
of 0.0026. Thus, the final primary analysis com-
pared the study groups at a two-sided alpha level 
of 0.048. The protocol specified a step-down test-
ing procedure, requiring that the test of the pri-
mary end point be significant before the key sec-
ondary end point was tested (also at an alpha 
level of 0.048).
R esult s
Patients
Between May 2004 and August 2008, a total of 9492 
patients underwent randomization at 440 study 
centers in 29 countries (Fig. 1). The intention-to-
treat cohort included 9406 patients after the ex-
clusion of 22 patients who did not provide consent 
and 64 patients from a single hospital for whom 
data could not be verified independently from 
source documents. Eleven patients were lost to fol-
low-up, and three patients had less than 27 days 
of follow-up. Baseline characteristics in the two 
study groups are shown in Table 1.
Clopidogrel Stratification
Investigators intended to provide early adminis-
tration of clopidogrel for 7057 patients (75.0%), 
although 5% of these patients did not receive the 
drug as intended. Investigators intended to defer 
a decision on the use of clopidogrel until after an-
giography for 2349 patients (25.0%), although 14% 
of these patients actually received the drug before 
angiography. The rate of intended early use of clo-
pidogrel was lower in North America than else-
where (50.8% vs. 85.8%).
Study Procedures
The median time from presentation to random-
ization was 5.6 hours. Nearly all patients (97.5%) 
underwent coronary angiography (median interval 
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after randomization, 21.4 hours). PCI was per-
formed in 59.1% of patients, CABG in 13.0%, and 
medical therapy without revascularization in 
28.3% (Table 1).
Of 5559 patients who underwent PCI, 1434 
(25.8%) received PCI kits (with transition to open-
label eptifibatide infusion) after angiography but 
before the wire crossed the lesion. Of these pa-
tients, 687 were in the early-eptifibatide group, and 
747 were in the delayed-eptifibatide group. The 
rates of use of PCI kits were 54.7% in North 
America and 15.1% elsewhere. An additional 648 
patients (11.7%) received bailout kits (312 in the 
early-eptifibatide group and 336 in the delayed-
eptifibatide group) after the wire crossed the 
lesion.
Efficacy End Points
The early administration of eptifibatide did not 
significantly reduce the rate of the primary com-
posite end point, as compared with the delayed, 
provisional administration of the drug (9.3% vs. 
10.0%; odds ratio, 0.92; 95% confidence interval 
[CI], 0.80 to 1.06; P = 0.23), nor did it significantly 
reduce the rate of the composite secondary end 
point of death or myocardial infarction at 30 days 
(11.2% vs. 12.3%; odds ratio, 0.89; 95% CI, 0.79 
to 1.01; P = 0.08) (Table 2, and Sections 3 and 4 in 
the Supplementary Appendix). There were no sig-
nificant differences between the study groups in 
the rate of death from any cause; in the rate of a 
composite of death, myocardial infarction, or re-
current ischemia requiring urgent revasculariza-
tion; in the rate of myocardial infarction alone; 
or in the rate of recurrent ischemia requiring ur-
gent revascularization alone.
There were no significant between-group in-
teractions with respect to prespecified baseline 
characteristics (including the investigator’s inten-
tion to administer clopidogrel early), the compos-
33p9
9406 Were included in the intention-to-treat
population
9492 Patients with high-risk acute coronary
syndromes without ST-segment elevation
were randomly assigned to treatment
86 Were excluded
64 Had unverifiable data
22 Did not provide written
consent 
4684 Were assigned to receive early placebo
with delayed eptifibatide before PCI
4722 Were assigned to receive early
eptifibatide
20 Had incomplete 30-day
follow-up data
9 Were lost to follow-up
10 Withdrew consent
1 Had early 30-day visit
8 Had incomplete 30-day
follow-up data
2 Were lost to follow-up
4 Withdrew consent
2 Had early 30-day visit
4664 Were available for follow-up
or had died at 30±3 days
121 (2.6%) Died before 30-day
visit
4714 Were available for follow-up
or had died at 30±3 days
134 (2.8%) Died before 30-day
visit
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Figure 1. Enrollment and Outcomes.
Data from 64 patients from a single hospital could not be confirmed and were excluded for all analyses. Among the 
patients in the delayed­eptifibatide group, 747 received active eptifibatide after angiography but before percutane­
ous coronary intervention (PCI), and an additional 336 received active eptifibatide after PCI had begun.
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ite primary end point (Fig. 2), or the composite 
secondary end point (Fig. 3).
No significant between-group differences in 
the rates of the primary or secondary end points 
were observed for patients who received only 
medical treatment or for those who received medi-
cal treatment before PCI or CABG (Fig. 4, and 
Section 5 in the Supplementary Appendix). Among 
patients who underwent PCI, those in the early-
eptifibatide group had fewer primary and second-
ary end points than those in the delayed-eptifib-
atide group.
Safety End Points 
Among patients in the early-eptifibatide group, 
118 patients had a TIMI major hemorrhage (2.6%), 
as compared with 83 in the delayed-eptifibatide 
group (1.8%) (odds ratio, 1.42; 95% CI, 1.07 to 
1.89; P = 0.02). With the severity of bleeding de-
fined according to the GUSTO (Global Utilization 
of Streptokinase and Tissue Plasminogen Activa-
tor for Occluded Coronary Arteries) criteria, the 
rate of moderate bleeding was 6.8% in the early-
eptifibatide group and 4.3% in the delayed-epti-
fibatide group (P<0.001); less severe bleeding was 
also significantly more frequent in the early-epti-
fibatide group. There was no significant between-
group difference in the rate of severe bleeding 
(0.8% in the early-eptifibatide group and 0.9% in 
the delayed-eptifibatide group, P= 0.97) (Table 2). 
The need for red-cell transfusion was increased 
in the early-eptifibatide group (8.6%, as com-
pared with 6.7% in the delayed-eptifibatide group; 
P = 0.001). There were no significant between-
group differences in the rates of thrombocytope-
nia, stroke, or surgical reexploration for bleeding; 
in the total volume of chest-tube drainage during 
the first 8 hours and 24 hours after CABG; or in 
the rate of serious adverse events (see Section 6 
in the Supplementary Appendix).
Discussion
We evaluated early administration of a glycopro-
tein IIb/IIIa inhibitor, eptifibatide, in patients who 
had high-risk acute coronary syndromes without 
ST-segment elevation and who were undergoing 
invasive therapies, with angiography mandated at 
12 to 96 hours after randomization. In compari-
son with earlier placebo-controlled trials of gly-
coprotein IIb/IIIa inhibitors in such patients,7-10 the 
patients in our trial were older, had higher-risk 
profiles, and were treated with more aggressive 
concomitant medical therapy and revasculariza-
tion. In this context, the early, routine adminis-
tration of double-bolus eptifibatide followed by a 
standard eptifibatide infusion was not superior to 
a strategy of early administration of placebo fol-
lowed by delayed, provisional administration of 
eptifibatide after angiography but before PCI. 
Among patients in the early-eptifibatide group, the 
trend toward fewer recurrent ischemic complica-
tions at 30 days was counterbalanced by more fre-
quent episodes of bleeding and need for trans-
fusions.
Previous studies investigating the use of gly-
coprotein IIb/IIIa inhibitors before PCI have had 
mixed results. As compared with placebo, the use 
of glycoprotein IIb/IIIa inhibitors reduced ische-
mic complications (predominantly periprocedural 
myocardial infarction) whether treatment was ini-
tiated early11 or just before PCI,3 even when 600 
mg of clopidogrel was administered.12 However, 
two small, randomized trials involving patients 
with acute coronary syndromes had conflicting 
findings regarding the effect of the early use of 
glycoprotein IIb/IIIa inhibitors, as compared with 
the use of such drugs immediately before PCI, on 
markers of myocardial necrosis.4,13 Furthermore, 
in the Acute Catheterization and Urgent Interven-
tion Triage Strategy (ACUITY) trial (ClinicalTrials.
gov number, NCT00093158),14 investigators could 
not rule out a benefit of as much as 29% with the 
early administration of glycoprotein IIb/IIIa in-
hibitors, nor did they show noninferiority of a 
strategy of delayed administration on the com-
posite ischemic end point.
In our trial, we used a superiority design to 
test strategies of early, routine use of eptifibatide 
versus early placebo before angiography, allowing 
a convergence of therapy in selected patients 
undergoing PCI (39% of patients in the delayed-
eptifibatide group received eptifibatide during 
PCI). This convergence precluded assessment of 
the benefit of eptifibatide, as compared with pla-
cebo. Therefore, our findings do not contradict 
earlier studies showing the superiority of glyco-
protein IIb/IIIa inhibitors over placebo in patients 
with acute coronary syndromes. In addition, there 
were important differences between our study and 
the ACUITY trial. In our study, randomization 
was required within 12 hours after presentation, 
the duration of exposure to a study drug before 
angiography was longer (21 hours vs. 4 hours), and 
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Table 1. Baseline Characteristics, Treatments, and Temporal Data.*
Characteristic
Early-Eptifibatide  
Group (N = 4722)
Delayed-Eptifibatide  
Group (N = 4684)
Demographic and clinical characteristics 
Age
Median — yr 67.4 67.8
Interquartile range — yr 60.0–74.8 60.3–75.3
≥75 yr — % 24.4 26.1
Female sex — % 32.0 31.2
Region of enrollment — %
North America 30.8 30.6
Western Europe 40.4 40.2
Eastern Europe 10.8 10.8
Middle East, Africa, or Asia–Pacific 18.0 18.3
Medical history — %
Diabetes mellitus 30.1 30.7
Dyslipidemia 57.9 57.8
Hypertension 70.5 71.9
Previous CABG 13.1 14.2
Previous myocardial infarction 27.0 28.2
Previous PCI 24.3 25.0
Estimated creatinine clearance†
Median — ml/min 74.7 73.7
Interquartile range — ml/min 56.2–96.2 55.7–96.2
<50 ml/min — % 18.3 18.4
Killip class II, III, or IV — % 11.3 11.1
Qualifying high­risk features — %
Age ≥60 yr, elevated biomarkers, and ST­segment changes 20.3 21.7
Age ≥60 yr and elevated biomarkers 41.8 42.1
Elevated biomarkers and ST­segment changes 14.4 14.5
Age ≥60 yr and ST­segment changes 11.5 10.6
Age 50–59 yr, elevated biomarkers, and previous vascular 
disease
5.9 5.6
Elevated troponin — % 83.8 84.0
Presentation to tertiary care hospital — % 81.3 81.0
Randomized ≤4 hr after presentation — % 34.0 32.6
TIMI risk score — %
Low (0–2) 17.2 15.9
Intermediate (3–4) 48.2 47.8
High (5–7) 34.6 36.2
Medical therapy during index hospitalization — %
Antithrombin
Unfractionated heparin only 33.8 35.1
Low­molecular­weight heparin only 53.4 52.4
Both unfractionated heparin and low­molecular­weight heparin 7.1 6.7
Neither unfractionated heparin nor low­molecular­weight heparin 5.8 5.8
Aspirin 97.4 97.3
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Table 1. (Continued.)
Characteristic
Early-Eptifibatide  
Group (N = 4722)
Delayed-Eptifibatide  
Group (N = 4684)
Medical therapy during index hospitalization — %
Clopidogrel
At any time 90.4 90.5
Early use intended 74.8 75.2
Beta­blocker 87.6 87.5
Statin 86.3 86.7
Angiotensin­converting–enzyme inhibitor 68.6 68.4
Angiotensin­receptor blocker 9.7 10.0
Temporal data and management strategy
Time from onset of symptoms to presentation — hr
Median 3.3 3.2
Interquartile range 1.4–8.0 1.5–7.8
Time from presentation to randomization — hr
Median 5.4 5.7
Interquartile range 3.3–8.8 3.4–8.8
Time from randomization to study­drug initiation — hr
Median 0.50 0.50
Interquartile range 0.25–0.88 0.25–0.88
Time from randomization to coronary angiography — hr
Median 21.4 21.4
Interquartile range 16.9–34.2 16.7–31.0
PCI — no. (%) 2761 (58.5) 2798 (59.7)
Time from randomization to PCI — hr
Median 22.0 22.1
Interquartile range 17.4–38.4 17.1–35.8
Duration of infusion before PCI — hr
Median 21.3 21.3
Interquartile range 16.8–37.9 16.4–34.9
Duration of infusion after PCI — hr
Median 18.8 19.0 
Interquartile range 17.6–22.1 17.8–22.3
CABG — no. (%) 621 (13.2) 606 (12.9)
Time from randomization to CABG — hr
Median 112.4 112.9
Interquartile range 62.7–182.5 62.8–185.9
Duration of infusion before CABG — hr
Median 44.6 47.0 
Interquartile range 24.0–74.2 26.5–74.5
Medical management only — no. (%) 1356 (28.7) 1304 (27.8)
Duration of infusion during medical management — hr
Median 30.3 31.4
Interquartile range 19.8–48.3 20.5–48.3
* Patients may have had more than one coexisting illness or received more than one type of drug during the index hospi­
talization. Statistical comparisons were not performed for baseline characteristics. Percentages may not total 100 be­
cause of rounding. CABG denotes coronary­artery bypass grafting, PCI percutaneous coronary intervention, and TIMI 
Thrombolysis in Myocardial Infarction.
† Creatinine clearance was calculated with the use of the Cockcroft–Gault formula.
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bivalirudin was used less frequently, since it was 
not required by design, as in the ACUITY trial.
A meta-analysis of six large, randomized tri-
als comparing glycoprotein IIb/IIIa inhibitors with 
placebo in patients with acute coronary syndromes 
in whom an invasive strategy was not mandated by 
protocol showed a relative reduction in the rate 
of death or myocardial infarction of 9% (95% CI, 
2 to 16) at 30 days.15 These findings are similar 
in magnitude to those that we report. Although 
due caution must be used in interpreting treat-
ment comparisons according to post-randomiza-
tion treatment strategies,16 among patients who 
had undergone PCI within 5 days after presenta-
tion, the relative reduction in the rate of death or 
myocardial infarction at 30 days was a more ro-
bust 23% (95% CI, 8 to 36), a finding that was 
similar to our observations after accounting for 
events before and after the invasive procedure. 
Furthermore, in this meta-analysis, the use of gly-
coprotein IIb/IIIa inhibitors was not associated 
with benefit for patients who did not have an 
elevated troponin level. Similarly, we observed no 
treatment benefit among patients with normal 
troponin levels; however, the treatment effect 
among patients with elevated levels was not as 
large as previously reported.
We postulate several explanations for the lack 
of significant treatment benefit with early, rou-
tine use of eptifibatide in our study. First, the 
convergence of use of eptifibatide during PCI in 
the two study groups probably reduced the dif-
ference in efficacy. However, we could not assign 
patients to a strict placebo group, since guide-
lines at the time that we were planning the trial 
strongly endorsed the use of glycoprotein IIb/IIIa 
inhibitors during PCI,17,18 and some regulatory 
agencies thought it would be unethical to with-
hold such drugs during PCI, given their efficacy 
in previous placebo-controlled trials.3,19 It is also 
possible that interventionalists simply identified 
correctly many of the patients who would bene-
fit from delayed, provisional use of eptifibatide. 
Furthermore, patients were treated with aggres-
sive contemporary cotherapies, including frequent 
use of clopidogrel (in >90% of patients), low-
molecular-weight heparin (60%), and statins (85%), 
which may have reduced the potential incremen-
tal effect of the early use of eptifibatide. Also, 
a greater-than-anticipated contribution to the pri-
mary end points of events that may not be modi-
fiable by antiplatelet therapy (e.g., procedural C
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complications) may have limited the benefit in 
the early-eptifibatide group. In addition, such a 
benefit may have been attenuated by the shorter 
time between presentation and PCI than in earlier 
placebo-controlled studies and by the substantial 
number of patients who were treated with CABG 
or medical therapy only. Finally, 1-year follow-up 
data in our trial are pending and may provide ad-
ditional insights, as occurred in a similar study.20
Although subgroup analyses should be inter-
preted with caution,21 our analysis of selected 
subgroups of patients (e.g., those who had a nor-
mal baseline troponin level, who did not have dia-
betes, and who were over the age of 75 years) 
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Figure 2. Odds Ratios and Rates of the Composite Primary End Point, According to Prespecified Subgroups.
Data for the composite primary end point — death from any cause, myocardial infarction, recurrent ischemia requiring urgent revascu­
larization, or the occurrence of a thrombotic complication during percutaneous coronary intervention (PCI) that required bolus therapy 
opposite to the initial study­group assignment (thrombotic bailout) — are shown. The percentages are the observed rates of the composite 
primary end point at 96 hours. For each subgroup, the size of the square is proportional to the number of patients and represents the 
odds ratio estimate for the treatment effect with adjustment for Cochran–Mantel–Haenszel analysis. The horizontal lines indicate 95% 
confidence intervals. The overall treatment effect in the early­eptifibatide group, as compared with that in the delayed­eptifibatide 
group, is represented by the diamond, and the dashed vertical line represents the corresponding overall odds ratio point estimate. 
None of the P values for interactions were significant.
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showed no evidence of a benefit with early ep-
tifibatide but did show an increased risk of 
bleeding. Our results argue against routine early 
initiation of treatment with glycoprotein IIb/IIIa 
inhibitors in such subgroups. Patients in our study 
who received early eptifibatide had fewer ischemic 
complications after PCI than those who received 
delayed eptifibatide, a finding that is consistent 
with current guidelines1,2 and previous studies22 
and that supports a continued role for such drugs 
in patients undergoing PCI.
Our results have important implications for 
the use of eptifibatide in patients with acute coro-
nary syndromes. First, the early, routine use of 
eptifibatide was not superior to provisional use 
during PCI. Second, patients in the early-eptifib-
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Figure 3. Odds Ratios and Rates of the Composite Secondary End Point, According to Prespecified Subgroups.
Data for the key secondary end points — death or myocardial infarction — are shown. The percentages are the observed rates of the 
key secondary composite end point at 30 days. For each subgroup, the size of the square is proportional to the number of patients and 
represents the odds ratio estimate for the treatment effect with adjustment for Cochran–Mantel–Haenszel analysis. The horizontal 
lines indicate 95% confidence intervals. The overall treatment effect in the early­eptifibatide group, as compared with that in the de­
layed­eptifibatide group, is represented by the diamond, and the dashed vertical line represents the corresponding overall odds ratio 
point estimate. The only significant P value for interaction was for sex (P = 0.046 by the Breslow–Day test).
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atide group had an increased risk of bleeding by 
a factor of 1.5 to 2.0. Even if subgroups of patients 
who might benefit from early eptifibatide treat-
ment could be identified, the risk of bleeding 
would have to be weighed against potential ben-
efits. If clinical or noninvasive assessments could 
reliably identify which patients with acute coro-
nary syndromes would have a substantially im-
proved outcome after PCI (as was recently shown 
in patients with stable angina23), selected sub-
groups might be considered for the early use of 
glycoprotein IIb/IIIa inhibitors.
In conclusion, in high-risk patients with acute 
coronary syndromes, the early, routine use of 
eptifibatide before PCI, as compared with early 
placebo followed by provisional eptifibatide, did 
not reduce the rate of the composite primary ef-
ficacy end point at 96 hours and was associated 
with a higher rate of non–life-threatening bleed-
ing and transfusion. However, in the early-eptifib-
atide group, there was a trend toward fewer re-
current ischemic events at 30 days. On the basis 
of these results, a routine strategy of administer-
ing eptifibatide in patients early after presentation 
cannot be recommended.
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Figure 4. Primary End-Point Events during Medical Therapy and after PCI or CABG.
Kaplan–Meier (KM) estimates of the rates of the primary efficacy end point are shown for patients who received medical therapy alone, 
those who underwent percutaneous coronary intervention (PCI), and those who underwent coronary­artery bypass grafting (CABG). 
Data on the interventional strategies were missing for eight patients (four in each study group). One death in the delayed­eptifibatide 
group that occurred 16 days after randomization was not included because data were missing regarding the use of revascularization. 
The 47 patients who underwent both CABG and PCI were categorized according to the procedure that was performed first. In the table 
below the flow chart, all events that occurred before PCI or CABG are included in the total number of events that occurred during medi­
cal therapy. All events that are shown are the first occurrence of the primary end point. The summaries are shown as the total number 
of events, along with the number at risk and Kaplan–Meier rate estimates. For event rates after revascularizations, events were counted 
after procedures were actually performed.
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tute — E. Veltri, S. Hildemann, J.T. Strony, A. Kilian, B. Yang; Millennium, Inc. — J. Gilbert. Steering Committee: Austria — K. Huber; 
Australia — P. Aylward; Canada — M. Labinaz, A. Langer, J.-F. Tanguay; Czech Republic — P. Widimsky; Denmark —  P. Grande; Finland 
— M. Lindroos; France — P.G. Steg; Germany — C. Bode, U. Zeymer; Hungary — M. Keltai; India — D. Prabhakaran; Israel — B.S. 
Lewis; Italy — D. Ardissino; the Netherlands — A. Van ‘t Hof; New Zealand — H. White; Norway — D. Atar; Poland — W. Ruzyllo; Portugal 
— P. Canas da Silva; Russia — V. Sulimov; South Africa — A. Dalby; Spain — A. Betriu; Switzerland — F. Mach; Sweden — S. James; United 
Kingdom — K. Fox, K. Karsch; United States — G. Brogan, J. Ferguson (through 2007), B. Gibler, H. Herrmann, J. Hochman, J. Hoekstra, 
N. Kleiman, E.M. Ohman, W. O’Neill, C. Pollack, Jr., M. Schweiger. Duke Clinical Research Institute Coordinating Center: Physician 
leadership — L.K. Newby (principal investigator), R.A. Harrington, P. Tricoci; Project leadership — L. Berdan; Lead statistician — J. White; 
Faculty statistician — K. Lee; Unblinded statistician — J. Leimberger; Clinical end-point committee (CEC) lead physician — M. Roe; CEC lead coordina-
tor — D. Montgomery; CEC event adjudication team — J. Alexander, M. Brennan, C. Bushnell, M. Chan, R. Lopes, D. Laskowitz, K. Ma-
haffey, R. Mehta, C. Melloni, J. Mills, G. Oliveira, M. Patel, J. Petersen, J. Piccini, B. Shah, P. Tricoci, T. Wang, K. Williams, S. Wiviott. 
Data management leads — C. Campbell, A. Heath. Data and Safety Monitoring Board: D. Weaver (chair), J. Alpert, E. Cohen, D. Faxon, L. 
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